Nigeria: Nigeria to Vaccinate 26 Million People in 2nd Phase of Biggest-Ever Yellow Fever Vaccination Campaign

[WHO] The Government of Nigeria - with support from the World Health Organization (WHO), Gavi, the Vaccine Alliance and UNICEF aims to vaccinate 26.2 million people during the second phase of its biggest-ever yellow fever campaign as it seeks to establish high population immunity nationwide.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

Publication date: 20–26 July 2019Source: The Lancet, Volume 394, Issue 10194Author(s): Paul Adepoju
Source: The Lancet - Category: General Medicine Source Type: research
Many flaviviruses including dengue (DENV), and Zika (ZIKV) have attracted significant attention in the past few years. As many flaviviruses are spread by arthropods, most of the world’s population is at risk of encountering a flavivirus, and infection with these viruses has created a significant disease burden worldwide. Vaccination against flaviviruses is thought to be one of the most promising avenues for reducing the disease burden associated with these viruses. The optimism surrounding a vaccine approach is supported by the highly successful vaccines for yellow fever and Japanese Encephalitis. Central to the deve...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
PMID: 31307078 [PubMed - in process]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tags: Ann Intern Med Source Type: research
sti M Abstract The stability of live-attenuated viruses is very challenging due to thermal sensitivity; therefore, solid form is usually required (often freeze-dried products). Micropellet technology is a lyophilization technology that has the potential to provide greater flexibility in the presentation of a given vaccine particularly in multi-dose format or in combination of different vaccines. As a novel vaccine alternative process, this spray freeze-dried (SFD) micropellet technology was evaluated using as a model a yellow fever virus produced in Vero cells (vYF). Screening of excipients was performed in order ...
Source: European Journal of Pharmaceutics and Biopharmaceutics - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Biopharm Source Type: research
Abstract Yellow fever virus (YFV) is a human flavivirus re-emerging in parts of the world. While a vaccine is available, large outbreaks have recently occurred in Brazil and certain African countries. Development of effective antiviral against YFV is crucial as there is no available effective drug against YFV. We have identified several novel nucleoside analogs with potent antiviral activity against YFV with EC50 values between 0.25 to 1 μM with selectivity indices over 100 in culture. PMID: 31262759 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
The present study aims to determine whether 17DD-YF-specific humoral and cellular immunological memory is maintained 8-years after primary vaccination with subdoses (10,447IU;3,013IU;587IU;158IU;31IU). Our results demonstrated that vaccinees, who had seroconverted following primary vaccination and had not been revaccinated, present similar neutralizing antibodies levels and YF-specific cellular memory, particularly CMCD4 and EMCD8 as compared to the reference full dose (27,476IU). Although, PRNT seropositivity rates were similar across subgroups (94%;82%;83%;94%;80% and 91%, correspondingly), only doses above 587IU elicite...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 13 June 2019Source: Antiviral ResearchAuthor(s): Anna Dubankova, Evzen BouraAbstractYellow fever virus (YFV) is responsible for devastating outbreaks of Yellow fever (YF) in humans and is associated with high mortality rates. Recent large epidemics and epizootics and exponential increases in the numbers of YF cases in humans and non-human primates highlight the increasing threat YFV poses, despite the availability of an effective YFV vaccine. YFV is the first human virus discovered, but the structures of several of the viral proteins remain poorly understood. Here we report the structure ...
Source: Antiviral Therapy - Category: Virology Source Type: research
We present Antigen-specific Lymphocyte Identification by Clustering of Expanded sequences (ALICE), a statistical approach that identifies TCR sequences actively involved in current immune responses from a single RepSeq sample and apply it to repertoires of patients w ith a variety of disorders—patients with autoimmune disease (ankylosing spondylitis [AS]), under cancer immunotherapy, or subject to an acute infection (live yellow fever [YF] vaccine). We validate the method with independent assays. ALICE requires no longitudinal data collection nor large cohorts , and it is directly applicable to most RepSeq datasets. ...
Source: PLoS Biology: Archived Table of Contents - Category: Biology Authors: Source Type: research
Abstract Yellow fever virus (YFV) is responsible for devastating outbreaks of Yellow fever (YF) in humans and is associated with high mortality rates. Recent large epidemics and epizootics and exponential increases in the numbers of YF cases in humans and non-human primates highlight the increasing threat YFV poses, despite the availability of an effective YFV vaccine. YFV is the first human virus discovered, but the structures of several of the viral proteins remain poorly understood. Here we report the structure of the full-length NS5 protein, a key enzyme for the replication of flaviviruses that contains both a...
Source: Antiviral Research - Category: Virology Authors: Tags: Antiviral Res Source Type: research
Dengue virus (DENV) is a member of the Flavivirus family that includes Zika virus (ZIKV), West Nile virus, Japanese encephalitis virus, and yellow fever virus. As the most prevalent of the flaviviruses, DENV is responsible for tens of millions of infections each year. The clinical manifestations of infection with one of the four DENV serotypes (DENV1–4) range from no symptoms to hemorrhagic fever and shock (“severe dengue”), which is fatal in ~25,000 patients annually. Many factors contribute to the development of severe dengue, including the DENV serotype and host expression of certain HLA alleles; howev...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: African Health | Government | International Medicine & Public Health | Nigeria Health | Vaccines | WHO | Yellow Fever | Yellow Fever Vaccination